RMD Resmed Inc
Price (delayed)
$231.69
Market cap
$34.03B
P/E Ratio
27.29
Dividend/share
$2.07
EPS
$8.49
Enterprise value
$34.35B
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory
Highlights
Resmed's debt has decreased by 40% YoY
RMD's net income is up by 40% YoY and by 12% QoQ
Key stats
What are the main financial stats of RMD
Market
Valuations
Earnings
Shares outstanding
146.87M
Market cap
$34.03B
Enterprise value
$34.35B
Price to earnings (P/E)
27.29
Price to book (P/B)
6.47
Price to sales (P/S)
6.9
EV/EBIT
22.1
EV/EBITDA
19.37
EV/Sales
6.97
Revenue
$4.93B
Gross profit
$2.88B
Operating income
$1.56B
Net income
$1.25B
EBIT
$1.55B
EBITDA
$1.77B
Free cash flow
$1.39B
Per share
Balance sheet
Liquidity
EPS
$8.49
EPS diluted
$8.47
Free cash flow per share
$9.48
Book value per share
$35.78
Revenue per share
$33.56
TBVPS
$26.55
Total assets
$7.14B
Total liabilities
$1.89B
Debt
$839.74M
Equity
$5.25B
Working capital
$1.98B
Debt to equity
0.16
Current ratio
3.33
Quick ratio
1.62
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
36%
Gross margin
58.4%
Net margin
25.3%
Operating margin
31.7%
Return on assets
17.8%
Return on equity
25%
Return on invested capital
45.6%
Return on capital employed
24.7%
Return on sales
31.5%
Dividend yield
0.89%
DPS
$2.07
Payout ratio
24.4%
RMD stock price
How has the Resmed stock price performed over time
Intraday
-0.47%
1 week
-0.55%
1 month
-6.5%
1 year
28.51%
YTD
1.31%
QTD
1.31%
Financial performance
How have Resmed's revenue and profit performed over time
Revenue
$4.93B
Gross profit
$2.88B
Operating income
$1.56B
Net income
$1.25B
Gross margin
58.4%
Net margin
25.3%
RMD's net income is up by 40% YoY and by 12% QoQ
RMD's operating income is up by 37% YoY and by 10% QoQ
Resmed's net margin has increased by 28% YoY and by 10% QoQ
RMD's operating margin is up by 25% year-on-year and by 7% since the previous quarter
Growth
What is Resmed's growth rate over time
Valuation
What is Resmed stock price valuation
P/E
27.29
P/B
6.47
P/S
6.9
EV/EBIT
22.1
EV/EBITDA
19.37
EV/Sales
6.97
The EPS has increased by 40% YoY and by 12% from the previous quarter
The price to earnings (P/E) is 36% lower than the 5-year quarterly average of 42.9 and 7% lower than the last 4 quarters average of 29.3
RMD's P/B is 27% below its 5-year quarterly average of 8.9 but 2.7% above its last 4 quarters average of 6.3
RMD's equity is up by 17% year-on-year
The P/S is 17% lower than the 5-year quarterly average of 8.3 but 3% higher than the last 4 quarters average of 6.7
The company's revenue rose by 9% YoY and by 2.5% QoQ
Efficiency
How efficient is Resmed business performance
The company's return on invested capital has surged by 57% YoY and by 15% QoQ
The ROA has increased by 36% YoY and by 11% from the previous quarter
The ROS has increased by 23% YoY and by 8% from the previous quarter
Resmed's ROE has increased by 18% YoY and by 8% from the previous quarter
Dividends
What is RMD's dividend history
DPS
$2.07
Dividend yield
0.89%
Payout ratio
24.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Resmed financials performed over time
Resmed's quick ratio has increased by 32% YoY and by 18% from the previous quarter
RMD's total liabilities is down by 22% year-on-year and by 7% since the previous quarter
Resmed's debt is 84% lower than its equity
Resmed's debt to equity has decreased by 48% YoY
Resmed's debt has decreased by 40% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.